

	Group / Unit name	<b>EXPERIMENTAL PNEUMOLOGY</b>								
	IP / Responsible	David RAMOS-BARBÓN								
	Staff	5: 1 IP; 1 post-doc; 1 pre-doc; 1 coordinadora de investigación clínica; 1 enfermera								
	Overview	La Unidad de Pneumología Experimental desarrolla proyectos de ciencia básica e investigación clínica. En su faceta básica, su eje son los modelos de asma experimental en ratón/rata, enfocados al estudio del papel de las células madre mesenquimales y los mecanismos de regulación inmunitaria en la remodelación de vías respiratorias. En su vertiente clínica, desarrolla y mantiene un biobanco especializado en biopsias bronquiales para investigación en asma, y efectúa sistemáticamente ensayos clínicos en fase II a IV para la industria farmacéutica, prioritariamente en asma y EPOC, incluyendo ensayos internacionales multicéntricos y ensayos unicéntricos de diseño propio para fases de desarrollo temprano.								
	Goals	Identificar mecanismos de enfermedad y dianas terapéuticas en el campo de la inflamación crónica y remodelación de vías respiratorias. Proporcionar a la industria de biotecnología y farmacéutica una plataforma para la ejecución de proyectos de desarrollo preclínico y ensayos clínicos.								
Research activity	Fields of interest	Asma; EPOC; inflamación; inmunorregulación; modelos animales; ensayos clínicos								
	Research subject	Epidemiology	Clinical	X	Pre-clinical	X	Basic	X	Translational	X
	10 Main Publications (last 5 years)	<ol style="list-style-type: none"> <li>1. Plaza V, <u>Ramos-Barbón D</u>, Muñoz AM, Fortuna AM, Crespo A, Murio C, Palomino R; EOLO Study Investigators. Exhaled Nitric Oxide Fraction as an Add-On to ACQ-7 for Not Well Controlled Asthma Detection. <i>PLoS One</i> 2013;8(10):e77085.</li> <li>2. Valdiglesias V, Kiliç G, Costa C, Amor-Carro O, Mariñas-Pardo L, <u>Ramos-Barbón D</u>, Méndez J, Pásaro E, Laffon B. In vivo genotoxicity assessment in rats exposed to Prestige-like oil by inhalation. <i>J Toxicol Environ Health A</i> 2012;75(13-15):756-64.</li> <li>3. De La Roque ED, Bellance N, Rossignol R, Begueret H, Billaud M, Santos PD, Ducret T, Marthan R, Dahan D, <u>Ramos-Barbón D</u>, Amor-Carro O, Savineau JP, Fayon M. DHEA reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats. <i>Eur Respir J</i> 2012; in press [Epub ahead of print Apr 20].</li> <li>4. <u>Ramos-Barbón D</u>, Parra-Arrondo A. [Inflammation and remodeling of the distal airways: studies in humans and experimental models]. <i>Arch Bronconeumol</i> 2011;47 (Suppl 2):2-9.</li> <li>5. <u>Ramos-Barbón D</u>. Resistance to glucocorticoids: another piece of the jigsaw. <i>Arch Bronconeumol</i> 2011;47(3):113-4.</li> <li>6. Brienza NS, Amor-Carro O, <u>Ramos-Barbón D</u>. An update on the use of indacaterol in patients with COPD. <i>Ther Adv Respir Dis</i> 2011;5(1):29-40.</li> <li>7. Vogelmeier C., <u>Ramos-Barbon D</u>, Jack D., Piggott S., Owen R., Higgins M., Kramer B. on behalf of INTIME study investigators. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with</li> </ol>								

		<p>tiotropium. <i>Respir Res</i> 2010;11:135.</p> <p>8. <u>Ramos-Barbón D.</u>, Fraga-Iriso R., Brienza N.S., Montero-Martínez C., Vereá H., Olivenstein R., Lemiere C., Ernst P., Hamid Q.A., Martín J.G. T cells localize with proliferating <math>\alpha</math>-SMA+ cell compartments in asthma. <i>Am J Respir Crit Care Med</i> 2010;182(3):317-24.</p>
	Main research Projects (last 5 years)	<ol style="list-style-type: none"> <li>1. SEPAR. The interaction between immune regulation and airway remodeling in asthma disease mechanisms: pathogenic outcomes versus therapeutic potential. 2012. 12,000 €</li> <li>2. Fundació Catalana de Pneumologia (FUCAP). The interaction between immune regulation and airway remodeling in asthma disease mechanisms: pathogenic outcomes versus therapeutic potential. 2012 Vifor Farma Award. 9,000.00 €</li> <li>3. FIS. The interaction between immune regulation and airway remodeling in asthma disease mechanisms: pathogenic outcomes versus therapeutic potential. PI11/01001. 156,540.12 €</li> <li>4. GlaxoSmithKline Collaborative Research Trial. The role of adult mesenchymal stem cells in asthma: contribution to airway remodeling versus immunoregulatory and therapeutic potential. 2010. 64,400.00 €</li> <li>5. SEPAR. Development of a biobank specialized in bronchial biopsy for asthma research. 09/862. 12,000.00 €</li> <li>6. FIS. Role of effector versus regulatory T cells in asthma airway remodeling and stem cell mechanisms. PI08/1822. 215,017.00 €</li> </ol>
	Stable International cooperations	<p>James G. Martin. McGill University, Montreal, Canada.</p> <p>Patrick Berger. Université Bordeaux-2, Burdeos, Francia.</p>
	Expertise	Asthma; COPD; Disease Animal Models; Clinical Trials.
Capacities & Resources	Technical skills	Rodent mechanical ventilation and pulmonary function testing; cell and molecular biology.
	Specific and singular Facilities & Equipment	Experimental pneumology laboratory, equipped with: mouse/rat mechanical ventilation & pulmonary function testing equipment; level-2 biocontainment facility for cell culture & gene transduction. Clinical trial facility (at <i>Centro de investigación de Medicamentos</i> ) with spirometry, ECG equipment and 6 beds for overnight/PK studies.
	Model Organims	<ul style="list-style-type: none"> <li>- Mouse and rat experimental asthma.</li> <li>- Retroviral cell gene transduction system for in vivo adoptive transfer.</li> </ul>
	Clinical guidelines &	

	Statements of Scientific Societies	
--	------------------------------------	--